Novo Nordisk

Page 5 of 9

Thomas Schinecker, chief executive officer of Roche
Finance

Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss

By
July 29, 2024
Thomas Schinecker, CEO of Roche Holding.
Retail

An obesity pill study tested on just 25 patients led to a stunning $16.8 billion increase in Swiss drugmaker Roche’s market value

By Naomi Kresge, Lisa Pham and Bloomberg
July 23, 2024
A bathroom scale is surrounded by colorful pills.
Health

Pharma giant Pfizer is trying to cash in on the weight loss drug craze with a new pill that could be a welcome needle-free alternative to pesky GLP-1 shots

By Damian Garde and Bloomberg
July 11, 2024
A person using Ozempic on November 2, 2023, in Madrid, Spain. Novo Nordisk, the Danish firm that manufactures Ozempic, has reported record quarterly results, up almost 3% on the stock market. The company's revenues rose by 38% to DKK 58.73 billion, some 7.8 billion euros. Ozempic is a diabetic drug that causes a loss of up to 15% of body weight because it acts as an appetite suppressant, a side effect that has made the drug fashionable on social media as a weight loss drug.
Features

Ozempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree

By Jessica Mathews and Alena Botros
July 9, 2024
Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
Health

Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs

By
June 28, 2024
Lars Fruergaard Jorgensen, CEO of Novo Nordisk.
Health

A rare setback as Ozempic-maker Novo Nordisk takes a $820 million hit as its next wonder drug fails

By Naomi Kresge and Bloomberg
June 27, 2024
EU urges clampdown on cosmetic misuse of Novo’s Ozempic amid worsening drug shortages for diabetics
Health

EU urges clampdown on cosmetic misuse of Novo’s Ozempic amid worsening drug shortages for diabetics

By Naomi Kresge and Bloomberg
June 26, 2024
Novo Nordisk’s Wegovy may have just two years to take over China’s market for weight-loss drugs
Tech

Novo Nordisk’s Wegovy may have just two years to take over China’s market for weight-loss drugs

By
June 26, 2024
Lars Fruergaard Jorgensen, CEO of Novo Nordisk.
Health

Novo Nordisk plots $4.1 billion in U.S. factory amid Ozempic shortage, the same day it pulled out of its Ireland development project

By Naomi Kresge and Bloomberg
June 25, 2024
Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk A/S, gestures while speaking during a Bloomberg Television interview in London, U.K.
Retail

Ozempic is 1,300% more expensive in the U.S. vs the U.K.—so the boss of Novo Nordisk is being hauled in front of Bernie Sanders to explain why

By
June 17, 2024
Plumes of smoke are seen after a fire broke out at an office building belonging to Danish pharmaceutical group Novo Nordisk in Bagsvaerd near Copenhagen, Denmark, on May 22, 2024.
Retail

Danish pharma giant Novo Nordisk’s office building is in danger of collapsing after a ‘massive fire’ broke out

By Sanne Wass, Naomi Kresge and Bloomberg
May 23, 2024
Nestle CEO Mark Schneider
Retail

Nestlé’s new foods are getting Ozempified, with slashed portions priced specifically for those on weight-loss drugs

By
May 21, 2024
Photo of two boys riding in a cargo bike with their mother in downtown of Copenhagen
Finance

Denmark’s economy shrinks 1.8% on reduced pharma production, showing extent of Novo Nordisk dependency

By Sanne Wass and Bloomberg
May 21, 2024
Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders
Retail

Bernie Sanders urges Danish pharma giant Novo Nordisk to lower its drug prices: ‘Help the American people’

By Christian Wienberg and Bloomberg
May 13, 2024
Dirk Van De Put, chairman and chief executive officer of Mondelez International.
Retail

People will keep eating Oreos despite Ozempic surge, according to CEO of maker, Mondelez

By Deena Shanker and Bloomberg
May 3, 2024

Most Popular